Estamos no ar no ! Saiba mais
187,31 USD
-1,85
0,98%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
187,31
0,00
0%
1 dia
-0,98%
5 dias
4,29%
1 mês
-3,38%
3 meses
-19,96%
6 meses
26,45%
No acumulado do ano
63,58%
1 ano
49,55%
5 anos
67,48%
10 anos
200,85%
 

Sobre: DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.

Funcionários: 78.000

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 42,4%
Neutro 48,5%
Negativo 9,1%
Neutro
PRNewsWire
ontem
DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
Seven studies spanning middle molecule clearance, home dialysis and patient experience highlight DaVita's commitment to translating innovation into better care DENVER, Oct. 15, 2026 /PRNewswire/ -- DaVita will present seven studies at the American Society of Nephrology (ASN) Kidney Week 2026, marking one of its most significant research presences at the conference in recent years. The research spans emerging approaches to middle molecule clearance, home dialysis and patient experience, underscoring DaVita's role in generating clinical evidence to help advance kidney care.
DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
Positivo
Zacks Investment Research
há 7 dias
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
In the latest trading session, DaVita HealthCare (DVA) closed at $179.25, marking a +1.26% move from the previous day.
Why DaVita HealthCare (DVA) Outpaced the Stock Market Today
Positivo
Seeking Alpha
há 7 dias
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again
DaVita is rated Buy with a $220 12-month price target, offering 22% upside from current levels. Despite flat industry volumes and Medicare rate headwinds, DVA's aggressive buybacks drive most EPS growth, enhancing per-share value. At $180, DVA trades at 9.4x forward earnings, making buybacks more accretive and capital allocation more effective than at recent highs.
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again
Positivo
Zacks Investment Research
há 7 dias
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DaVita gains from IKC growth, improving treatment economics and stronger formulary adoption, but payer-mix pressures and costs remain concerns.
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
Neutro
PRNewsWire
há 8 dias
DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
Patients encouraged to confirm treatment schedules, prepare emergency supplies and contact DaVita for assistance DENVER, Oct. 8, 2026 /PRNewswire/ -- As Hurricane Isaias approaches the Gulf Coast and southeastern United States, DaVita has activated its emergency response plan to help patients continue receiving life-sustaining dialysis care and to support communities preparing for severe weather. The storm is expected to bring heavy rainfall, flooding, storm surge and high winds across portions of the region.
DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
Neutro
The Motley Fool
há 10 dias
3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs
American Express is the last remaining credit card stock in Berkshire's portfolio. The New York Times Company is bucking the trend of the struggling newspaper industry.
3 Berkshire Hathaway Holdings to Buy While They Sit at Least 15% Below Their Highs
Neutro
Zacks Investment Research
há 14 dias
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $178.69, denoting a +1.33% move from the preceding trading day.
DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
Positivo
The Motley Fool
há 17 dias
This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.
DaVita reported double-digit EPS growth in the second quarter. Berkshire Hathaway owns roughly 45% of DaVita stock.
This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.
Neutro
Zacks Investment Research
há 22 dias
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw DaVita HealthCare (DVA) settling at $174.67, representing a -4.62% change from its previous close.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
Positivo
MarketBeat
há 25 dias
3 Surging Stocks That Don't Need the AI Boom to Keep Winning
With AI companies—and related chip stocks—driving much of the market's performance this year, it's understandable that some investors are hesitant to put all their trust in a burgeoning industry, no matter how much momentum it seems to have. Fortunately, a number of non-AI stocks have stood out for their strong performance throughout the first part of 2026.
3 Surging Stocks That Don't Need the AI Boom to Keep Winning
Gráficos de preços implementados com Lightweight Charts™